Caladrius Biosciences to Participate at the 2017 Cell & Gene Meeting on the Mesa

BASKING RIDGE, N.J., Sept. 28, 2017 -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces today that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present at the upcoming Cell and Gene Meeting on the Mesa being held October 4-6, 2017 in La Jolla, California.

Dr. Mazzo will present a corporate overview including an update on recent clinical progress in The Sanford Project: T-Rex Study of CLBS03 at the Partnering Forum Event on Thursday, October 5, 2017 at 9:15 a.m. Pacific time.

A live video webcast of the presentation will be available at http://www.caladrius.com/events and will also be archived for 90 days following the event.

Organized by the Alliance for Regenerative Medicine and the Sanford Stem Cell Clinical Center at UC San Diego, The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry's premier annual Partnering Forum, the first event of its kind dedicated solely to facilitating connections in this sector. Combined, these meetings attract over 850 attendees, fostering key partnerships through more than 1100 one-on-one meetings while highlighting the significant clinical and commercial progress in the field. 

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. For more information on Caladrius please visit www.caladrius.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.

Contacts:
Investors:

Caladrius Biosciences, Inc.
John Menditto
Executive Director, Investor Relations and Corporate Communications
Phone:  +1-908-842-0084
Email: [email protected]

LHA Investor Relations
Anne Marie Fields
Senior Vice President
Phone: +1-212-838-3777
Email: [email protected]        

Media:
Caladrius Biosciences, Inc.
Terrance Beckett
Associate Manager, Communications and Marketing
Phone: +1-646-434-2681
Email: [email protected]